Press Releases

10/04 Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells AQ
01/04 Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease GL
24/03 Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration GL
23/03 Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy GL
04/03 Ocugen: Q4 Earnings Snapshot AQ
04/03 Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results GL
03/03 Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone AQ
02/03 Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa GL
18/02 Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results GL
09/02 Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer GL
23/01 Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock GL
21/01 Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock GL
15/01 Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration GL
13/01 Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data GL
12/01 Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference AQ
12/01 Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy GL
09/01 Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference GL
10/12 Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit GL
20/11 Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference GL
20/11 Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference AQ
17/11 Resetting retinal networks with a gene-agnostic approach AQ
05/11 Ocugen: Q3 Earnings Snapshot AQ
05/11 Ocugen Provides Business Update with Third Quarter 2025 Financial Results GL
23/25/23 Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results GL
02/25/02 Ocugen to Present at Industry and Investor Conferences in October 2025 GL
No results for this search